Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James F Howard

Showing results (81-90 of 117) with videos related to

Pageof 12
Sort By:
Therapeutic Advances in Neurological Disorders|September 24, 2024
Maintenance of zilucoplan efficacy in patients with generalised myasthenia gravis up to 24 weeks: a model-informed analysisGuillemette de la Borderie, Damien Chimits, Babak Boroojerdi, et al.
Neurology|April 19, 2023
Addressing Outcome Measure Variability in Myasthenia Gravis Clinical TrialsJeffrey T Guptill, Michael Benatar, Volkan Granit, et al.
The Lancet. Neurology|June 19, 2021
Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trialJames F Howard, Vera Bril, Tuan Vu, et al.
Muscle & Nerve|May 7, 2021
Telemedicine visits in myasthenia gravis: Expert guidance and the Myasthenia Gravis Core Exam (MG-CE)Amanda C Guidon, Srikanth Muppidi, Richard J Nowak, et al.
The Lancet. Neurology|June 23, 2023
Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b/2a studyVolkan Granit, Michael Benatar, Metin Kurtoglu, et al.
Muscle & Nerve|March 21, 2013
A randomized, double-blind, placebo-controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravisJames F Howard, Richard J Barohn, Gary R Cutter, et al.
The Lancet. Neurology|October 26, 2017
Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre studyJames F Howard, Kimiaki Utsugisawa, Michael Benatar, et al.
Therapeutic Advances in Neurological Disorders|July 7, 2025
Switching to subcutaneous zilucoplan from intravenous complement component 5 inhibitors in generalised myasthenia gravis: a phase IIIb, open-label studyMiriam Freimer, Urvi Desai, Raghav Govindarajan, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|September 3, 2024
Subcutaneous efgartigimod PH20 in generalized myasthenia gravis: A phase 3 randomized noninferiority study (ADAPT-SC) and interim analyses of a long-term open-label extension study (ADAPT-SC+)James F Howard, Tuan Vu, George Li, et al.
Expert Review of Clinical Immunology|April 29, 2025
Safety profile of efgartigimod from global clinical trials across multiple immunoglobulin G-mediated autoimmune diseasesKelly G Gwathmey, Catherine M Broome, Matthias Goebeler, et al.
Pageof 12

Showing results (81-90 of 117) with videos related to

Sort By:
Pageof 12
Therapeutic Advances in Neurological Disorders|September 24, 2024
Maintenance of zilucoplan efficacy in patients with generalised myasthenia gravis up to 24 weeks: a model-informed analysisGuillemette de la Borderie, Damien Chimits, Babak Boroojerdi, et al.
Neurology|April 19, 2023
Addressing Outcome Measure Variability in Myasthenia Gravis Clinical TrialsJeffrey T Guptill, Michael Benatar, Volkan Granit, et al.
The Lancet. Neurology|June 19, 2021
Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trialJames F Howard, Vera Bril, Tuan Vu, et al.
Muscle & Nerve|May 7, 2021
Telemedicine visits in myasthenia gravis: Expert guidance and the Myasthenia Gravis Core Exam (MG-CE)Amanda C Guidon, Srikanth Muppidi, Richard J Nowak, et al.
The Lancet. Neurology|June 23, 2023
Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b/2a studyVolkan Granit, Michael Benatar, Metin Kurtoglu, et al.
Muscle & Nerve|March 21, 2013
A randomized, double-blind, placebo-controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravisJames F Howard, Richard J Barohn, Gary R Cutter, et al.
The Lancet. Neurology|October 26, 2017
Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre studyJames F Howard, Kimiaki Utsugisawa, Michael Benatar, et al.
Therapeutic Advances in Neurological Disorders|July 7, 2025
Switching to subcutaneous zilucoplan from intravenous complement component 5 inhibitors in generalised myasthenia gravis: a phase IIIb, open-label studyMiriam Freimer, Urvi Desai, Raghav Govindarajan, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|September 3, 2024
Subcutaneous efgartigimod PH20 in generalized myasthenia gravis: A phase 3 randomized noninferiority study (ADAPT-SC) and interim analyses of a long-term open-label extension study (ADAPT-SC+)James F Howard, Tuan Vu, George Li, et al.
Expert Review of Clinical Immunology|April 29, 2025
Safety profile of efgartigimod from global clinical trials across multiple immunoglobulin G-mediated autoimmune diseasesKelly G Gwathmey, Catherine M Broome, Matthias Goebeler, et al.
Pageof 12